Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 29;2(12):1513–1532. doi: 10.1002/hep4.1270

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

OCA treatment reduces hepatic inflammation in 34‐week HFD‐fed Ldlr‐/‐.Leiden mice. Mice were treated with OCA (10 mg/kg/day) from t = 24 weeks to t = 34 weeks. (A) OCA‐treatment tended to reduce the number of inflammatory clusters in liver. (B) The number of F4/80+ CLS was reduced by OCA. (C) OCA significantly increased the ratio of Arg1 to CD68 mRNA expression. The ratio of CD11c to CD68 mRNA expression (D) and CCR2 to CD68 mRNA expression (E) tended to be reduced in HFD+OCA relative to HFD. OCA tended to enhance the disappearance of CD4+ (F) and CD8+ (G) cells. Data are mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 versus HFD at 34 weeks.